Christopher J. Sayed, MD, reports on how the 2025 American Academy of Dermatology Annual Meeting was an exciting event for hidradenitis suppurativa (HS), with increasing buzz and interest in the condition. The conference featured three key sessions, including one on special populations, another on the pathophysiology and treatment updates for HS, and a smaller session on office-based procedures such as cryoinsufflation.
GLP-1 receptor agonists sparked debate regarding their role in dermatology, with some excitement over their potential impact on comorbidities such as diabetes, though more evidence is needed. One of the major highlights was the promising 2-year data on bimekizumab, showing strong results in treating HS and signaling the continued growth of effective treatment options for patients.
